Gemcitabine, oxaliplatin, leucovorin, and 5-fluorouracil (GOLF) is a novel multidrug regimen inducing high levels of necrosis and apoptosis in colon carcinoma cells. This regimen is also able to promote a process of Ag remodeling including up-regulation of immunotherapy targets like carcinoembryonic Ag (CEA), thymidylate synthase (TS). We have conducted a preclinical study aimed to investigate whether these drug-induced modifications would also enhance colon cancer cell immunogenicity. Several CTL lines were thus generated by in vitro stimulating human HLA-A(*)02.01(+) PBMCs, from normal donors and colon cancer patients, with autologous dendritic cells cross-primed with cell lysates of colon cancer cells untreated, irradiated, or previously exposed to different drug treatments including the GOLF regimen. Class I HLA-restricted cytolytic activity of these CTL lines was tested against colon cancer cells and CEA and TS gene transfected target cells. These experiments revealed that CTLs sensitized with GOLF-treated cancer cells were much more effective than those sensitized with the untreated colon carcinoma cells or those exposed to the other treatments. CTL lines sensitized against the GOLF-treated colon cancer cells, also expressed a greater percentage of T-lymphocyte precursors able to recognize TS- and CEA-derived peptides. These results suggest that GOLF regimen is a powerful antitumor and immunomodulating regimen that can make the tumor cells a suitable means to induce an Ag-specific CTL response. These results suggest that a rationale combination of GOLF chemotherapy with cytokine-based immunotherapy could generate a chemotherapy-modulated Ag-specific T-lymphocyte response in cancer patients able to destroy the residual disease survived to the cytotoxic drugs.

Correale, P., Cusi, M., Del Vecchio, M., Aquino, A., Prete, S., Tsang, K., et al. (2005). Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. JOURNAL OF IMMUNOLOGY, 175(2), 820-828.

Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro

AQUINO, ANGELO;PRETE, SALVATORE;BONMASSAR, ENZO;
2005-01-01

Abstract

Gemcitabine, oxaliplatin, leucovorin, and 5-fluorouracil (GOLF) is a novel multidrug regimen inducing high levels of necrosis and apoptosis in colon carcinoma cells. This regimen is also able to promote a process of Ag remodeling including up-regulation of immunotherapy targets like carcinoembryonic Ag (CEA), thymidylate synthase (TS). We have conducted a preclinical study aimed to investigate whether these drug-induced modifications would also enhance colon cancer cell immunogenicity. Several CTL lines were thus generated by in vitro stimulating human HLA-A(*)02.01(+) PBMCs, from normal donors and colon cancer patients, with autologous dendritic cells cross-primed with cell lysates of colon cancer cells untreated, irradiated, or previously exposed to different drug treatments including the GOLF regimen. Class I HLA-restricted cytolytic activity of these CTL lines was tested against colon cancer cells and CEA and TS gene transfected target cells. These experiments revealed that CTLs sensitized with GOLF-treated cancer cells were much more effective than those sensitized with the untreated colon carcinoma cells or those exposed to the other treatments. CTL lines sensitized against the GOLF-treated colon cancer cells, also expressed a greater percentage of T-lymphocyte precursors able to recognize TS- and CEA-derived peptides. These results suggest that GOLF regimen is a powerful antitumor and immunomodulating regimen that can make the tumor cells a suitable means to induce an Ag-specific CTL response. These results suggest that a rationale combination of GOLF chemotherapy with cytokine-based immunotherapy could generate a chemotherapy-modulated Ag-specific T-lymphocyte response in cancer patients able to destroy the residual disease survived to the cytotoxic drugs.
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore BIO/14
Settore MED/06 - Oncologia Medica
English
Con Impact Factor ISI
carcinoembryonic antigen; etoposide; fluorouracil; folinic acid; gemcitabine; HLA A antigen; HLA antigen class 1; irinotecan; oxaliplatin; thymidylate synthase; antineoplastic activity; apoptosis; article; cancer immunotherapy; carcinoma cell; cell lysate; colon carcinoma; controlled study; cross presentation; cytotoxic T lymphocyte; dendritic cell; flow cytometry; genetic transfection; haplotype; human; human cell; immunoblotting; immunogenicity; immunomodulation; peripheral blood mononuclear cell; priority journal; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Coculture Techniques; Colonic Neoplasms; Cross-Priming; Cytotoxicity, Immunologic; Dendritic Cells; Deoxycytidine; Drug Evaluation, Preclinical; Fluorouracil; HLA-A Antigens; HT29 Cells; Humans; Leucovorin; Leukocytes, Mononuclear; Organoplatinum Compounds; T-Lymphocytes, Cytotoxic
Correale, P., Cusi, M., Del Vecchio, M., Aquino, A., Prete, S., Tsang, K., et al. (2005). Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. JOURNAL OF IMMUNOLOGY, 175(2), 820-828.
Correale, P; Cusi, M; Del Vecchio, M; Aquino, A; Prete, S; Tsang, K; Micheli, L; Nencini, C; La Placa, M; Montagnani, F; Terrosi, C; Caraglia, M; Formica, V; Giorgi, G; Bonmassar, E; Francini, G
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
J.imm.pdf

accesso aperto

Descrizione: j immun
Dimensione 395.08 kB
Formato Adobe PDF
395.08 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/42137
Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact